How does lurbinectedin compare to standard ovarian cancer treatments?

Lurbinectedin is approved for platinum-sensitive relapsed small cell lung cancer, not ovarian cancer. It is an alkylating agent that binds DNA major groove, disrupts transcription, tumor microenvironment, and tumor-supporting macrophages. It works differently from taxanes, platinum agents, and PARP inhibitors.

How does lurbinectedin compare with platinum-based regimens?

Lurbinectedin shows a 35% objective response rate in platinum-sensitive small cell lung cancer patients who progressed after first-line therapy. The median progression-free survival is 4.3 months and median overall survival 9.3 months. [1] In ovarian cancer studies, it has produced 18–30% response rates in platinum-sensitive cases and 0–15% in platinum-resistant cases. Those figures liegen unterhalb der response rates seen with platinum re-challenge itself, which usually exceeds 40%.